

Reference number
1829-H

SPECIALTY QUANTITY LIMIT PROGRAM

ALUNBRIG (brigatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Alunbrig 30 mg tablets	120 per 30 days	150 per 30 days	<ul style="list-style-type: none"> • 90 mg once daily for the first 7 days; if tolerated, increase to 180 mg once daily • The following dosage adjustments may be necessary: <ul style="list-style-type: none"> - 120 mg daily - 90 mg daily - 60 mg daily • Up to a maximum of twice the dose may be necessary when coadministered with certain CYP inducers
Alunbrig 90 mg tablets	53 per 30 days	Not applicable	
Alunbrig 180 mg tablets	30 per 30 days	60 per 30 days	
Alunbrig Initiation Pack [180 mg tablets (#23), 90 mg tablets (#7)]	30 per 30 days	Not applicable	

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Alunbrig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; December 2018.